Currently, white blood cell (WBC) tests are performed via invasive blood draws that must be carried out at health centers or specialized facilities. This setup, which requires patient travel, inherently limits the frequency of testing—limiting medical professionals’ ability to monitor their patients’ health. This limitation is especially troubling for chemotherapy patients. During each treatment cycle, these patient’s WBCs will drop significantly in reaction to chemotherapy, leaving them at risk of life-threatening infections. Due to the limited WBC testing availability, doctors currently do not know exactly when and how long their patients are at risk. As a consequence, every year in the US, 110,000 patients -almost 20% of all chemo patients- end up hospitalized due one of these infections. These episodes worsen their clinical outcomes and lead to hospital admissions that increase care cost by $25,000 per case. Leuko is addressing this problem by developing a home-based, non-invasive WBC analyzer that provides more frequent monitoring enabling physicians to prescribe medication (e.g. prophylactic antibiotics) to effectively reduce the risk of infection and reduce unnecessary hospital admissions.
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.